Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other



Auffarth Gerd Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 4 Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns: Granted 210,225 options to buy @ $0.24, valued at $50.5k
03/31/2023 4 Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns: Granted 41,065 options to buy @ $1.05, valued at $43.1k
10/07/2022 4 Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns: Granted 42,239 options to buy @ $1.25, valued at $52.8k
03/24/2022 4 Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns: Granted 21,878 options to buy @ $1.92, valued at $42k
10/07/2021 4 Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns: Granted 25,245 options to buy @ $2.12, valued at $53.5k
03/26/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/05/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/21/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/06/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2020 4 Auffarth Gerd (Director) has filed a Form 4 on Outlook Therapeutics, Inc.
Txns: Granted 25,000 options to buy @ $0.72, valued at $18k
04/21/2020 3 Auffarth Gerd (Director) has filed a Form 3 on Outlook Therapeutics, Inc.
12/19/2018 4 Auffarth Gerd (Director) has filed a Form 4 on Presbia PLC
Txns: Granted 81,743 options to buy @ $0.53, valued at $43.3k
07/20/2018 4 Auffarth Gerd (Director) has filed a Form 4 on Presbia PLC
Txns: Granted 67,981 options to buy @ $2, valued at $136k
03/22/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
03/10/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
08/09/2016 4 Auffarth Gerd (Director) has filed a Form 4 on Presbia PLC
Txns: Granted 8,247 shares @ $0

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy